Draw/line
Education and research purposes only, not medical advice. Unapproved compounds are not for human consumption. Check every result with your prescriber. Disclaimer Research and education only. Not medical advice. Disclaimer
Home / Compounds / KLOW blend

KLOW blend: BPC-157, TB-500, GHK-Cu and KPV

KLOW is a seller's name for one vial sold as the GLOW blend plus KPV: BPC-157, TB-500, GHK-Cu and KPV. That makeup is as sellers describe it; we found no medical source describing KLOW. No human trial of the blend exists.

4 compounds · Not FDA-approved · Reviewed

Not approved by the FDA for human use. Not for human consumption. This page describes KLOW blend only to explain its regulatory status, what has been studied and its known risks. Drawline does not recommend obtaining or using it. Disclaimer

FDA status

BPC-157: Not approved for any use. FDA flagged it for safety concerns in 2023. In July 2026 an FDA advisory committee narrowly recommended adding it to the list of substances pharmacies may compound. The vote is advisory. It is not FDA approval, and nothing changes legally until FDA finishes rulemaking. The use the committee considered was ulcerative colitis. FDA staff had advised that it did not meet the standard for listing. In October 2026 HHS published a draft policy saying it does not intend to take action against pharmacies and physicians that compound it under set conditions while FDA decides through rulemaking. That is a decision not to enforce, not approval, and it can be withdrawn.

TB-500: Not approved for any use. In July 2026 an FDA advisory committee narrowly recommended adding it to the list of substances pharmacies may compound. The vote is advisory. It is not FDA approval, and nothing changes legally until FDA finishes rulemaking. The use the committee considered was wound healing. In October 2026 HHS published a draft policy saying it does not intend to take action against pharmacies and physicians that compound it under set conditions while FDA decides through rulemaking. That is a decision not to enforce, not approval, and it can be withdrawn.

GHK-Cu: Not approved as a drug. FDA flagged the injectable form in 2023. An advisory committee review is expected before the end of February 2027.

KPV: Not approved for any use. FDA placed it in September 2023 among bulk substances that may present significant safety risks in compounding (Category 2), then took it out of that category on April 22, 2026, ahead of an advisory review; HHS says neither step changed its legal status. In July 2026 an FDA advisory committee narrowly voted to recommend it for the list of substances pharmacies may compound, for wound healing and inflammatory conditions, against the advice of FDA staff. The vote is advisory. In October 2026 HHS published a draft policy that lists it among peptides it does not intend to act against when pharmacies compound them under set conditions while FDA decides through rulemaking. That is a decision not to enforce, not approval, and it can be withdrawn.

Evidence

BPC-157: Almost entirely animal and laboratory studies. Published human data cover only a few dozen people.

TB-500: No published human trials of TB-500 itself. FDA has pointed out that human studies of thymosin beta-4 are not evidence for TB-500.

GHK-Cu: Some human evidence for topical use on skin. No human studies support injecting it.

KPV: FDA found no clinical studies or human exposure data for KPV by any route. The research is in cells and mice, such as studies in which it reduced chemically induced colitis.

No study has tested these compounds together in one vial in people.

Risks

BPC-157: Long-term safety in people is unknown. It is banned in sport at all times under the World Anti-Doping Code.

TB-500: Safety in people is unknown. It is banned in sport at all times under the World Anti-Doping Code.

GHK-Cu: FDA has cited a risk of immune reactions with injectable products because of possible aggregation and impurities.

KPV: FDA says it lacks important information about whether KPV would cause harm in people. Like other injected peptides, compounded or research products can carry impurities and clumps that may trigger immune reactions. Sport: it is not named on the WADA Prohibited List, but no health authority has approved it for human use, so it falls under class S0 (non-approved substances), banned at all times.

Products sold for "research use only" carry no assurance of identity, strength or sterility. In a blend you cannot set the amounts separately: every draw carries each compound in the ratio mixed into the vial.

Sport

BPC-157: It is banned in sport at all times under the World Anti-Doping Code.

TB-500: It is banned in sport at all times under the World Anti-Doping Code.

GHK-Cu: It is not named on the 2026 WADA Prohibited List. Athletes should check any unapproved injectable with their anti-doping agency.

KPV: It is not named on the WADA Prohibited List, but no health authority has approved it for human use, so it falls under class S0 (non-approved substances), banned at all times.

Related

Each compound has its own profile: BPC-157, TB-500, GHK-Cu, KPV. See also the Wolverine blend and the 2026 regulatory tracker.

Questions

What is in KLOW blend?

BPC-157, TB-500, GHK-Cu and KPV. As sold by sellers; no medical source describes it.

Is KLOW blend FDA-approved?

No. There is no approved product combining these compounds, and BPC-157, TB-500, GHK-Cu, KPV are not approved for any use.

Sources: AJMC: FDA panel backs 6 peptides for compounding; Pharmacy Times: what the peptide vote changes; Black Health: what the FDA peptide vote changed; HHS: enforcement discretion policy for compounding certain peptides (draft); Federal Register: HHS draft peptide compounding policy, October 30, 2026; Worst Pills, Best Pills: unapproved peptides; FDA: bulk drug substances that may present significant safety risks; WADA: 2026 Prohibited List; FDA: KPV briefing document, July 2026; FDA: Pharmacy Compounding Advisory Committee, July 23 and 24, 2026; HHS: peptides covered by the draft enforcement discretion policy (Appendix B); Dalmasso et al., KPV reduces intestinal inflammation in mice (2008).

For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.

Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.